Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERGONAL vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pergonal (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from postmenopausal urine. It stimulates ovarian follicular growth and maturation in women and spermatogenesis in men by acting on specific gonadal receptors.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Induction of ovulation in patients with polycystic ovary disease or anovulatory infertility not due to primary ovarian failure,Stimulation of multiple follicular development in ovulatory patients undergoing assisted reproductive technologies (ART),Induction of spermatogenesis in men with hypogonadotropic hypogonadism (in combination with h CG)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
Intramuscular administration: 75 IU daily for 7-12 days, then 5,000-10,000 IU h CG 24 hours after last dose.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life approximately 24-36 hours; clinical context: supports daily dosing in ovulation induction protocols.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Menotropins are metabolized via proteolytic degradation in the liver and kidneys. The metabolic pathways involve hydrolysis into amino acids and smaller peptides.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Primarily renal: 70-80% as unchanged drug and metabolites within 24 hours; biliary/fecal excretion accounts for <5%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 10-15% bound to serum albumin.
92% bound primarily to albumin
Vd approximately 0.5-0.6 L/kg, indicating distribution limited to extracellular fluid.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Intramuscular: approximately 100% bioavailability; subcutaneous: approximately 80-90% relative to IM.
Oral: 85% with high first-pass effect; IM: 100%
No specific guidelines; use with caution in renal impairment as drug excretion may be reduced.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not indicated for pediatric use; no weight-based guidelines established.
Not approved for pediatric use.
Not typically used in elderly; consider age-related decline in ovarian response and increased risk of adverse events.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
Pergonal should only be used by physicians who are experienced in fertility disorders and in settings where monitoring of estradiol levels and follicular development through ultrasound is possible. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and is characterized by sudden ovarian enlargement, ascites, pleural effusion, oliguria, and thromboembolic events. Multiple births are increased.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Ovarian hyperstimulation syndrome (OHSS),Thromboembolic events,Ovarian torsion,Ovarian enlargement,Multiple gestation,Ectopic pregnancy,Spontaneous abortion,Ovarian neoplasms (long-term use),Pulmonary complications (atelectasis, acute respiratory distress syndrome)
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Pituitary tumor,Ovarian cyst or enlargement of unknown origin,Abnormal vaginal bleeding of undetermined cause,Pregnancy,Sex hormone-dependent tumors (e.g., breast, uterus)
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No known food interactions. Maintain adequate hydration to help reduce the risk of OHSS; avoid excessive alcohol or caffeine as they may contribute to dehydration.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
Pergonal (menotropins) is a gonadotropin used for ovulation induction. In vitro studies show no evidence of teratogenicity; however, there is a risk of multiple gestation (20% twinning rate, higher order multiples less common). No specific fetal malformations are attributed to the drug. First trimester exposure is not associated with major congenital anomalies. Second and third trimester risks are minimal as the drug is not continued after pregnancy is achieved.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
No data available on excretion into breast milk. Pergonal is not indicated during breastfeeding. The M/P ratio is unknown. Due to the hormonal nature and potential for adverse effects in infants, breastfeeding is not recommended during therapy.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
No dosing adjustments are required in pregnancy because Pergonal is discontinued once pregnancy is confirmed. Treatment is typically stopped after ovulation and conception. Pharmacokinetic changes in pregnancy do not apply as the drug is not used during gestation.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
Pergonal (menotropins) is a human menopausal gonadotropin used for ovulation induction. Monitor estradiol levels and follicular growth via ultrasound to minimize ovarian hyperstimulation syndrome (OHSS) and multiple gestation. Administer IM only; do not use if solution is cloudy or contains particles. Concomitant use with Gn RH agonists may require dose adjustments. Discontinue if severe ovarian enlargement or pain occurs.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
This medication is injected into a muscle; your healthcare provider will show you how to prepare and give the injection.,You will need frequent blood tests and ultrasound exams to monitor your response to the medication and reduce risks.,The most common serious side effects are ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy. Notify your doctor immediately if you experience severe pelvic pain, bloating, nausea, vomiting, or rapid weight gain.,Store unused vials in the refrigerator; do not freeze. Protect from light. Discard any unused portion after opening.,Do not use if you are already pregnant or have ovarian cysts, abnormal vaginal bleeding, thyroid or adrenal disorders, or pituitary tumors.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERGONAL vs ANTAGONATE, answered by our medical review team.
PERGONAL is a Gonadotropin that works by Pergonal (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from postmenopausal urine. It stimulates ovarian follicular growth and maturation in women and spermatogenesis in men by acting on specific gonadal receptors.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERGONAL and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERGONAL is: Intramuscular administration: 75 IU daily for 7-12 days, then 5,000-10,000 IU h CG 24 hours after last dose.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERGONAL and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERGONAL is classified as Category C. Pergonal (menotropins) is a gonadotropin used for ovulation induction. In vitro studies show no evidence of teratogenicity; however, there is a risk of multiple gestation (20% twin. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.